Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease (ETHERAL-US)

Oryzon Genomics

Status and phase: Completed; Phase 2

Conditions: Mild to Moderate Alzheimer's Disease

Treatments: Drug: ORY-2001 High dose; Drug: Placebo; Drug: ORY-2001 Low dose

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03867253

CL05-ORY-2001US

Details and patient eligibility

About

This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.

Full description

This phase IIa study is a double-blind, randomized, parallel-group and multicenter study with a placebo-controlled 24-week treatment period followed by a no placebo-controlled 24-week extension period.

It is planned to randomise 25 patients. In the double-blind placebo-controlled treatment period, all patients will be randomized between two doses of ORY-2001 and placebo. In the double-blind no placebo-controlled extension period, patients in the placebo arm will be re-allocated in one of the two different dose levels of ORY-2001. Randomization will be stratified by cognitive impairment severity.

An independent Data Monitoring Committee (DMC) will review un-blinded safety data throughout the study.

Enrollment: 24 patients

Sex: All

Ages: 50 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Probable Alzheimer's Disease (AD) diagnosed according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
• MMSE score at Screening and Baseline Visits of at least 16 and not greater than 26
• Evidence of the AD pathophysiological process indicated by decreased levels of amyloid antigen binding (AB) and increased levels of total Tau protein or phospho-Tau protein in cerebrospinal fluid (CSF)
• Outpatient consulting a general practitioner, or a psychiatrist/neurologist/geriatrician
• Knowledgeable and reliable close relative/caregiver who will accompany the patient to all clinic visits during the study
• Daily treatment with the same acetylcholinesterase inhibitor on a stable dose
• Fertile male and female must use highly effective contraception, from the Screening Visit until 90 days after last dose.
• Signed informed consent by patient (or legal representative, if applicable) and a close relative/caregiver prior to the initiation of any study specific procedure

Exclusion criteria

• Failure to perform screening or baseline examinations

• Hospitalization or change of concomitant medication 1 month prior to Screening visit or during Screening Period

• Clinical, laboratory or neuroimaging findings consistent with:

  1. Other primary degenerative dementia;
  2. Other neurodegenerative condition;
  3. Cerebrovascular disease;
  4. Other central nervous system diseases;

• A current Diagnostic and Statistical Manual-5 (DSM-5) diagnosis of major depression, schizophrenia or bipolar disorder

• Positive results for tuberculosis, human immunodeficiency virus (HIV), hepatitis C or hepatitis B (hepatitis B surface antigen [HbsAg]) serology at the Screening Visit

• Clinically significant, advanced or unstable disease that may interfere with evaluation.

• Disability that may prevent the patients from completing all study requirements.

• Chronic drug intake of forbidden concomitant medication.

• Treatment with anti-amyloid beta or anti-Tau protein monoclonal antibodies or other disease modifying strategies within three months or five half-lives, whichever is longer, prior to the Screening Visit

• Treatment with an active vaccine targeting amyloid beta or Tau protein

• Suspected or known drug or alcohol abuse

• Metallic implants or any other cause precluding the performance of brain MRI

• Enrolment in another investigational study or intake of investigational drug within the previous 3 months since the last dose

• Suicide attempt within the last year or significant risk of suicide (in the opinion of the investigator, defined as a "yes" to suicidal ideation questions 4 or 5, or answering "yes" to suicidal behavior on the Columbia-Suicide Severity Rating Scale within the past 12 months)

• Any condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

24 participants in 3 patient groups, including a placebo group

ORY-2001 Low dose

Active Comparator group

Description:

0.6mg ORY-2001 capsule

Treatment:

Drug: ORY-2001 Low dose

ORY-2001 High dose

Active Comparator group

Description:

1.2mg ORY-2001 capsule

Treatment:

Drug: ORY-2001 High dose

Placebo

Placebo Comparator group

Description:

Placebo capsule

Treatment:

Drug: Placebo